Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex.

Diez-Alarcia R, Ibarra-Lecue I, Lopez-Cardona ÁP, Meana J, Gutierrez-Adán A, Callado LF, Agirregoitia E, Urigüen L.

Front Pharmacol. 2016 Nov 4;7:415.

2.

Orexins contribute to restraint stress-induced cocaine relapse by endocannabinoid-mediated disinhibition of dopaminergic neurons.

Tung LW, Lu GL, Lee YH, Yu L, Lee HJ, Leishman E, Bradshaw H, Hwang LL, Hung MS, Mackie K, Zimmer A, Chiou LC.

Nat Commun. 2016 Jul 22;7:12199. doi: 10.1038/ncomms12199.

3.

Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats.

Besheer J, Frisbee S, Randall PA, Jaramillo AA, Masciello M.

Neuropharmacology. 2016 Feb;101:216-24. doi: 10.1016/j.neuropharm.2015.09.027.

4.

Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.

Maguire DR, France CP.

Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):249-57. doi: 10.1097/FBP.0000000000000192.

PMID:
26397756
5.

Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Picone RP, Kendall DA.

Mol Endocrinol. 2015 Jun;29(6):801-13. doi: 10.1210/me.2015-1062. Review.

6.

The role of varenicline on alcohol-primed self-administration and seeking behavior in rats.

Randall PA, Jaramillo AA, Frisbee S, Besheer J.

Psychopharmacology (Berl). 2015 Jul;232(14):2443-54. doi: 10.1007/s00213-015-3878-1.

7.

Individual differences in response to positive and negative stimuli: endocannabinoid-based insight on approach and avoidance behaviors.

Laricchiuta D, Petrosini L.

Front Syst Neurosci. 2014 Dec 22;8:238. doi: 10.3389/fnsys.2014.00238. Review.

8.

Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future.

Panagis G, Mackey B, Vlachou S.

Front Psychiatry. 2014 Jul 31;5:92. doi: 10.3389/fpsyt.2014.00092. Review.

9.

Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli.

Laricchiuta D, Musella A, Rossi S, Centonze D.

Front Behav Neurosci. 2014 May 19;8:183. doi: 10.3389/fnbeh.2014.00183.

10.

CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats.

Wills KL, Vemuri K, Kalmar A, Lee A, Limebeer CL, Makriyannis A, Parker LA.

Psychopharmacology (Berl). 2014 Nov;231(22):4291-300. doi: 10.1007/s00213-014-3575-5. Erratum in: Psychopharmacology (Berl). 2014 Nov;231(22):4419-20.

11.

Role of cues and contexts on drug-seeking behaviour.

Perry CJ, Zbukvic I, Kim JH, Lawrence AJ.

Br J Pharmacol. 2014 Oct;171(20):4636-72. doi: 10.1111/bph.12735. Review.

12.

Orexin/hypocretin role in reward: implications for opioid and other addictions.

Baimel C, Bartlett SE, Chiou LC, Lawrence AJ, Muschamp JW, Patkar O, Tung LW, Borgland SL.

Br J Pharmacol. 2015 Jan;172(2):334-48. doi: 10.1111/bph.12639. Review.

13.

The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food.

Dore R, Valenza M, Wang X, Rice KC, Sabino V, Cottone P.

Addict Biol. 2014 Sep;19(5):849-61. doi: 10.1111/adb.12056.

14.

Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Panlilio LV, Justinova Z, Goldberg SR.

Pharmacol Ther. 2013 Apr;138(1):84-102. doi: 10.1016/j.pharmthera.2013.01.003. Review.

15.

Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.

Ramesh D, Gamage TF, Vanuytsel T, Owens RA, Abdullah RA, Niphakis MJ, Shea-Donohue T, Cravatt BF, Lichtman AH.

Neuropsychopharmacology. 2013 May;38(6):1039-49. doi: 10.1038/npp.2012.269.

16.

Hub and switches: endocannabinoid signalling in midbrain dopamine neurons.

Melis M, Pistis M.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3276-85. doi: 10.1098/rstb.2011.0383. Review.

17.

Braking dopamine systems: a new GABA master structure for mesolimbic and nigrostriatal functions.

Barrot M, Sesack SR, Georges F, Pistis M, Hong S, Jhou TC.

J Neurosci. 2012 Oct 10;32(41):14094-101. doi: 10.1523/JNEUROSCI.3370-12.2012. Review.

18.

Endocannabinoids and the processing of value-related signals.

Melis M, Muntoni AL, Pistis M.

Front Pharmacol. 2012 Feb 2;3:7. doi: 10.3389/fphar.2012.00007.

19.

Contrasting Effects of Lithium Chloride and CB1 Receptor Blockade on Enduring Changes in the Valuation of Reward.

Hernandez G, Bernstein D, Schoenbaum G, Cheer JF.

Front Behav Neurosci. 2011 Sep 6;5:53. doi: 10.3389/fnbeh.2011.00053.

20.

Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Serrano A, Parsons LH.

Pharmacol Ther. 2011 Dec;132(3):215-41. doi: 10.1016/j.pharmthera.2011.06.005. Review.

Items per page

Supplemental Content

Support Center